Are you attending this year’s PERNEFRI Annual Meeting? Come and visit us at our booth (#3-4) and find out what’s new at Fresenius Medical Care.
High Volume HDF improves patient survival
The Catalonian Online Haemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from haemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment. At this year’s ERA-EDTA Congress, HighVolumeHDF was the main focus of Fresenius Medical Care’s activities.
Cardiovascular and non-cardiovascular mortality rates for people commencing haemodialysis are nearly 30 to 50 times higher than for the general population. It has been suggested that removal of larger solutes across high-flux haemodialysis membranes may better reflect normal kidney function and improve cardiovascular outcomes versus low-flux haemodialysis. Here we report results from a meta-analysis investigating this hypothesis.
The ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) aims to encourage and report advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects1. Here we provide information on their International Clinical Fellowship Program now open to young Asian investigators and clinicians including those in Indonesia.